Poly Medicure Limited — Updates, 08-08-2025: Press Release

Poly Medicure delivered strong Q1 FY26 results. Consolidated revenue grew 10.7% YoY, fueled by robust 20.1% domestic market expansion, despite a slight dip in international sales due to global tensions. Profit After Tax rose 25.5%, with a 20.9% PAT margin. Operating EBITDA margin was 26.3%. Key operational strides include 46.2% growth in Renal care, 130 dialysis machines sold, new stent clinical registry, and two contract manufacturing wins. The company also launched a Brazil subsidiary to expand presence, while maintaining zero net debt.